Literature DB >> 17324553

Development of the Treatment Adherence Survey-patient version (TAS-P) for OCD.

Maria C Mancebo1, Anthony Pinto, Steven A Rasmussen, Jane L Eisen.   

Abstract

This paper reports on the development and initial psychometric evaluation of the Treatment Adherence Survey-patient version (TAS-P), a brief instrument designed to assess patient adherence to Cognitive-Behavioral Therapy (CBT) and pharmacotherapy recommendations for OCD. Eighty individuals with Obsessive Compulsive Disorder (OCD) were administered the TAS-P as part of the intake interview of a prospective, observational study of the course of OCD. Results demonstrated excellent test-retest reliability. Responses on the TAS-P were also significantly correlated with scores on a self-report measure of general treatment adherence and with data collected from a chart-review, demonstrating concurrent validity. Treatment adherence was not explained by demographic variables. However, participants who reported nonadherence to CBT recommendations had more severe OCD symptoms at the time of intake than those who did not endorse CBT nonadherence (mean Y-BOCS = 23.27 +/- 7.5 versus 18.20 +/- 8.0, respectively). Results suggest that the TAS-P is a promising instrument for assessing reasons for nonadherence to recommendations for CBT and pharmacotherapy interventions.

Entities:  

Mesh:

Year:  2007        PMID: 17324553      PMCID: PMC3858011          DOI: 10.1016/j.janxdis.2007.01.009

Source DB:  PubMed          Journal:  J Anxiety Disord        ISSN: 0887-6185


  13 in total

1.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

2.  Success and failure in the behavioral treatment of obsessive-compulsives.

Authors:  E B Foa; J B Grayson; G S Steketee; H G Doppelt; R M Turner; P R Latimer
Journal:  J Consult Clin Psychol       Date:  1983-04

3.  The adequacy of pharmacotherapy in outpatients with obsessive-compulsive disorder.

Authors:  D Denys; H Van Megen; H Westenberg
Journal:  Int Clin Psychopharmacol       Date:  2002-05       Impact factor: 1.659

4.  Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder.

Authors:  G O'Sullivan; H Noshirvani; I Marks; W Monteiro; P Lelliott
Journal:  J Clin Psychiatry       Date:  1991-04       Impact factor: 4.384

5.  The Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake.

Authors:  Anthony Pinto; Maria C Mancebo; Jane L Eisen; Maria E Pagano; Steve A Rasmussen
Journal:  J Clin Psychiatry       Date:  2006-05       Impact factor: 4.384

6.  Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.

Authors:  Edna B Foa; Michael R Liebowitz; Michael J Kozak; Sharon Davies; Rafael Campeas; Martin E Franklin; Jonathan D Huppert; Kevin Kjernisted; Vivienne Rowan; Andrew B Schmidt; H Blair Simpson; Xin Tu
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

7.  The Modified Hamilton Rating Scale for Depression: reliability and validity.

Authors:  I W Miller; S Bishop; W H Norman; H Maddever
Journal:  Psychiatry Res       Date:  1985-02       Impact factor: 3.222

8.  Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.

Authors:  J H Greist; J W Jefferson; K A Kobak; D J Katzelnick; R C Serlin
Journal:  Arch Gen Psychiatry       Date:  1995-01

9.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11
View more
  7 in total

1.  Prevalence and clinical characteristics of mental rituals in a longitudinal clinical sample of obsessive-compulsive disorder.

Authors:  Nicholas J Sibrava; Christina L Boisseau; Maria C Mancebo; Jane L Eisen; Steven A Rasmussen
Journal:  Depress Anxiety       Date:  2011-08-04       Impact factor: 6.505

2.  Patient utilization of cognitive-behavioral therapy for OCD.

Authors:  Maria C Mancebo; Jane L Eisen; Nicholas J Sibrava; Ingrid R Dyck; Steven A Rasmussen
Journal:  Behav Ther       Date:  2011-03-05

3.  Who qualifies for deep brain stimulation for OCD? Data from a naturalistic clinical sample.

Authors:  Sarah L Garnaat; Benjamin D Greenberg; Nicholas J Sibrava; Wayne K Goodman; Maria C Mancebo; Jane L Eisen; Steven A Rasmussen
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2014       Impact factor: 2.198

4.  Design and Rationale for a Randomized Controlled Trial Testing the Efficacy of Aerobic Exercise for Patients with Obsessive-Compulsive Disorder.

Authors:  Ana M Abrantes; Nicole McLaughlin; Benjamin D Greenberg; David R Strong; Deborah Riebe; Maria Mancebo; Steven Rasmussen; Julie Desaulniers; Richard A Brown
Journal:  Ment Health Phys Act       Date:  2012-06-30

5.  A review of studies concerning treatment adherence of patients with anxiety disorders.

Authors:  Lívia Santana; Leonardo F Fontenelle
Journal:  Patient Prefer Adherence       Date:  2011-08-23       Impact factor: 2.711

6.  Development of an Item Bank to Measure Medication Adherence: Systematic Review.

Authors:  Yu Heng Kwan; Livia Jia Yi Oo; Dionne Hui Fang Loh; Truls Østbye; Lian Leng Low; Hayden Barry Bosworth; Julian Thumboo; Jie Kie Phang; Si Dun Weng; Dan V Blalock; Eng Hui Chew; Kai Zhen Yap; Corrinne Yong Koon Tan; Sungwon Yoon; Warren Fong
Journal:  J Med Internet Res       Date:  2020-10-08       Impact factor: 5.428

7.  Measurement Properties of Existing Patient-Reported Outcome Measures on Medication Adherence: Systematic Review.

Authors:  Yu Heng Kwan; Si Dun Weng; Dionne Hui Fang Loh; Truls Østbye; Lian Leng Low; Hayden Barry Bosworth; Julian Thumboo; Jie Kie Phang; Livia Jia Yi Oo; Dan V Blalock; Eng Hui Chew; Kai Zhen Yap; Corrinne Yong Koon Tan; Sungwon Yoon; Warren Fong
Journal:  J Med Internet Res       Date:  2020-10-09       Impact factor: 5.428

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.